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doi:10.1Objective: The purpose of this analysis was to evaluate a novel strategy for reporting adverse events in the
Pediatric Heart Network’s randomized surgical trial of systemic–pulmonary artery shunt versus right
ventricle–pulmonary artery conduit in infants with hypoplastic left heart syndrome. The strategy was developed
to align the reporting process with the needs of a surgical trial while maintaining participant safety.
Methods: Adverse event reporting was analyzed for 2 groups of study subjects: those randomized to a trial arm
during a period in which a standard adverse event reporting system was used (period 1) and those randomized
after institution of a system that focused serious adverse event reporting on 6 sentinel events (period 2). The
analysis encompassed the period from randomization (Norwood surgery) to hospital discharge from stage II sur-
gery. Adverse event rates were compared using a Poisson regression model for the number of events per subject.
Results: From period 1 to period 2, the rate of serious adverse events requiring expedited reporting decreased as
expected (0.42 vs 0.14/subject/month of follow-up; P<.001). Subjects with a serious (sentinel) adverse event in
period 2 had a significantly higher rate of death and cardiac transplantation.
Conclusions: The new adverse event reporting system successfully targeted subjects at highest risk, while de-
creasing the administrative burden associated with adverse event reports. This methodology may be of benefit in
trials evaluating surgical or device-based interventions and in critically ill populations where many common
clinical events would qualify as serious adverse events in the context of a drug trial. (J Thorac Cardiovasc
Surg 2011;142:531-7)Little has been published on adverse event (AE) reporting in
pediatric research. There is even less experience with AE
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The Journal of Thoracic and Casearch, and there is no regulatory guidance specific to con-
ducting clinical research in critically ill children. Recent
publications have standardized the definitions of a number
of complications and AEs for patients undergoing treatment
for congenital and pediatric heart diseases,1,2 but few, if any,
publications examine strategies for reporting and grading
the severity of these complications and AEs in pediatric
cardiac surgical trials.
The Pediatric Heart Network (PHN) was established by
the National Heart, Lung, and Blood Institute (NHLBI), Na-
tional Institutes of Health (NIH), in 2001 to conduct multi-
center studies in children with congenital and acquired heart
disease.3 Early PHN protocols4,5 effectively used standard
principles for reporting AEs that adhered to the criteria
for defining serious AEs (Table 1). These general principles
are established by the International Conference on Harmo-
nisation, a body of clinical trial guidance derived from the
collaborative efforts of the United States, European Union,
and Japan and implemented by the federal Office of Human
Research Protections and the Food and Drug Administra-
tion.6,7 Coding dictionaries or classification systems are
used to augment this guidance and provide a standardized
approach to reporting AEs in clinical studies. The PHN
used the Common Terminology Criteria for Adverserdiovascular Surgery c Volume 142, Number 3 531
Abbreviations and Acronyms
AE ¼ adverse event
CTCAE ¼ Common Terminology Criteria for
Adverse Events
DCC ¼ Data Coordinating Center
DSMB ¼ Data and Safety Monitoring Board
IRB ¼ institutional review board
NHLBI ¼ National Heart, Lung, and Blood
Institute
NIH ¼ National Institutes of Health
PHN ¼ Pediatric Heart Network
SAE ¼ serious adverse event
SVR ¼ Single Ventricle Reconstruction trial
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DEvents (CTCAE), version 3.0, developed by the National
Cancer Institute, NIH. These principles and tools
provided standard definitions of AEs and serious adverse
events (SAEs), a system of severity scoring, and reporting
guidelines, designed particularly for drug trials.
The limitations of the standard AE reporting approaches
became apparent during the PHN’s Infant Single Ventricle
Trial, which compared treatment with enalapril to placebo
in critically ill infants with single ventricle physiology.8,9
There were not enough appropriate pediatric CTCAE
codes to cover the complexity of this trial population, and
the CTCAE severity scale was not developed for trials in
critically ill infants. Discussions, training, and close
monitoring for the duration of the trial were implemented
to refine our approach to AE reporting.
Then in May 2005, the PHN launched the Single Ventri-
cle Reconstruction (SVR) Trial, a randomized trial compar-
ing a systemic–pulmonary artery shunt versus a right
ventricle–pulmonary artery conduit in infants with hypo-
plastic left heart syndrome undergoing initial surgical palli-
ation.10,11 The SVR trial began with a standard AE
reporting framework modified on the basis of lessons
learned in the Infant Single Ventricle Trial, but it soon
became clear that an AE reporting system based on the
standard strategy for drug studies was inappropriate for
this surgical trial. The specific challenge was that many
clinical events that are common in the postoperative
period qualify as serious AEs in the context of a drug
trial; thus the standard reporting paradigm resulted in
excessive reporting while providing a disproportionately
small amount of useful safety information. Moreover, the
large number of reports generated considerable
administrative workload for individual investigators, study
coordinators, and institutional review boards (IRBs)/
research ethics boards as well as the NIH, the data
coordinating center, the medical monitor, and the Data
and Safety Monitoring Board (DSMB).532 The Journal of Thoracic and Cardiovascular SurgTo enhance the ability to recognize clinically meaningful
events, PHN investigators turned to the sentinel event con-
cept. A sentinel event, as defined by the Joint Commission
on Accreditation of Healthcare Organizations, is an unex-
pected occurrence involving death or serious physical or
psychological injury, or the risk thereof, that signals the
need for immediate investigation and response.12 In
a research context, sentinel perinatal events have been iden-
tified that predict patterns of brain injury.13
The purpose of this analysis was to compare two AE re-
porting methods used in the SVR trial to assess the accuracy
of predicting the most severe adverse outcomes in the study
population and the associated changes in reporting burden.
PATIENTS AND METHODS
Patient Population
The design of the SVR trial has been described8 and the main results re-
ported.9 Neonates with hypoplastic left heart syndrome and other single
right ventricle malformations were enrolled at 8 main PHN clinical sites
and 7 SVR auxiliary sites. Subjects were randomized to receive a Norwood
procedure with either a modified right Blalock–Taussig shunt or right
ventricle–pulmonary artery conduit to provide pulmonary blood flow.
The primary end point was death or transplant at 12 months. The protocol
for the SVR trial was approved by each center’s IRB, and written informed
consent was obtained from a parent or guardian.
Safety Monitoring and AE Reporting Processes
The SVR trial protocol underwent review by an independent DSMB ap-
pointed by NHLBI to oversee all PHN studies and was subsequently ap-
proved by the IRBs at all sites, including the PHN Data Coordinating
Center (DCC). AEs were recorded and submitted by the site team via a se-
cure, web-based electronic data capture system to the DCC, with immedi-
ate reporting of SAEs to the DCC, NHLBI, and the independent PHN
medical monitor, a pediatric cardiologist with expertise in cardiac critical
care. Sites reported AEs/SAEs to their IRBs as dictated by local require-
ments. The DSMB reviewed study data every 6 months, and a summary
of this review was sent to the local IRB to ensure that all participating
centers were informed of any pertinent safety findings.
SAEs were initially defined in the SVR trial as events that met the cri-
teria in Table 1. In this phase of the SVR trial, May 2005 to January 2007,
referred to here as period 1, each AE and SAE was recorded and submitted
to the DCC. The events were categorized in standard fashion as to the de-
gree of relatedness to the trial intervention. The site investigator catego-
rized the response to the AE as surgical or catheter intervention, medical
therapy, or none; the clinical outcome was characterized as resolved or
stabilized.
A revised approach, developed by the SVRAdverse Events Subcommit-
tee, was implemented from February 2007 to trial end in October 2009 (pe-
riod 2). The SVR AE subcommittee included congenital heart surgeons,
pediatric cardiologists and cardiac intensivists, study coordinators, the
AE coordinator from the DCC, and NHLBI staff. The subcommittee
reviewed the limited published literature and obtained information from
pediatric investigators who had been involved in previous operative and
perioperative surgical trials.14-16 An AE framework was established
consistent with the concept of the sentinel event in patient safety literature.
Six ‘‘sentinel’’ SAEs, considered sufficiently serious for the SVR trial
population, were identified (Table 2) and triggered expedited reporting.
The frequency of these events was known from published retrospective
outcome reports on neonates with hypoplastic left heart syndrome after
Norwood palliation,17-19 so there was a precedent for determining the
number of reported events. Following standard practice, in addition toery c September 2011
TABLE 2. SVR sentinel SAEs during period 2
SVR Sentinel SAEs
 Death
 Acute shunt failure
 Cardiac arrest requiring CPR and medications
 Cardiopulmonary insufficiency requiring ECMO
 Cardiovascular reoperation (unplanned)
 Necrotizing enterocolitis requiring laparotomy
SVR, Single Ventricle Reconstruction; SAE, serious adverse event; CPR, cardiopul-
monary resuscitation; ECMO, extracorporeal membrane oxygenation.
TABLE 1. Criteria for definition of SAEs during period 1, SVR trial
Criteria for definition of SAEs, SVR trial
 Fatal
 Life-threatening
 Severely or permanently disabling
 Necessitates significant intervention, such as major surgery, to prevent
permanent impairment of a body function or permanent damage to
a body structure
 Necessitates or prolongs hospital admission
 PI, medical monitor, or DSMB considers the event to be an SAE
SAE, Serious adverse event; SVR, Single Ventricle Reconstruction; PI, principal
investigator; DSMB, Data and Safety Monitoring Board.
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Dthese 6 events, any other event that the site principal investigator
considered to be an SAE was also reported in expedited fashion. Death,
1 of the 6 sentinel SAEs, was also a primary study end point and
required a separate reporting format to the DSMB to preserve the
statistical integrity of the final trial data analysis.
During period 2, all events that were not sentinel SAEs were captured in
the trial database as complications rather than AEs, using a standardized
code list organized by organ system that was developed for this purpose
(Table 3). Complications were recorded on an abbreviated case report
form, which replaced the detailed AE reporting forms previously used.
The SVR trial protocol was amended to reflect these changes, approved
by the DSMB and NHLBI, and approved by the IRB at each site. Training
sessions were held to familiarize study personnel with the new procedures,
and the DCC AE coordinator worked individually with sites to ensure
a smooth transition on the effective date of the change.
Data Analysis
Data analysis was performed to evaluate the effectiveness of the new
approach in achieving the goals of facilitating the detection of important
safety end points and decreasing the volume of expedited reporting of
events. Data were analyzed for 2 groups of study subjects: those random-
ized during period 1 (May 2005–January 2007) and those randomized dur-
ing period 2 (February 2007–October 2009). The clinical period of interest
for this analysis was from randomization (Norwood surgery) up to hospital
discharge from stage II surgery. AEs occurring after the predefined follow-
up window were not included. The data of subjects who had not been
discharged from the stage II surgery within the period windowwere consid-
ered incomplete and also excluded from analysis. The number of SAEs,
AEs, and complications was determined from the case report forms.
SAE, AE, and complication incidence rates were compared, accounting
for varying follow-up time in each AE reporting period, to normalize the
raw numbers of events. A Poisson regression model for the number of
events per subject was used to compare the SAE rates of the 2 time periods.
In addition to comparing SAE rates, the new reporting system was vali-
dated by assessing the rates of death or transplant in the 2 time periods
among those for whom an SAE was reported. Event rates in this report
are based on the complete trial data set. NHLBI staff participated in the
analysis and interpretation of the data for this article.RESULTS
During periods 1 and 2, a total of 247 and 224 subjects
were randomized and followed up as described earlier. Av-
erage follow-up time during period 1 was 3.9  2.3 months
(median, 4.3 months) compared with 4.7 2.3 months (me-
dian, 4.8 months) during period 2; the difference results
from normalizing the raw numbers of events. In period 1,
81% of subjects had an SAE reported, compared withThe Journal of Thoracic and Ca48% in period 2 (Table 4). From period 1 to period 2, the
number of reported SAEs decreased by 64%, and the
SAE incidence decreased by 67%. This represented a sig-
nificant drop (by design) in the SAE rate (0.42 vs 0.14
events/subject/month of follow-up; P< .001). The inci-
dence of complications in period 2 was 1.0 event/subject/
month of follow-up.
The 1-year death/transplant rate associated with patients
who had a sentinel SAE reported under the new system was
1.4 times higher (66% vs 46%; P ¼ .001) than the rate as-
sociated with patients who had an SAE reported under the
original system, which included a broader range of clinical
AEs. The 1-year death/transplant rates were similar (5% vs
3%; P ¼ .484) for patients who had only a nonserious AE
(period 1 designation) and those who had only a complica-
tion (period 2 designation).
Because the number of events reported as SAEs de-
creased 64% from 406 in period 1 to 147 in period 2
(Table 4), the number of case report forms submitted to
the DCC also decreased by two-thirds. The information re-
quested in the SAE forms did not change from period 1 to
period 2.DISCUSSION
Standard AE reporting practices for drug trials were inad-
equate in this randomized cardiovascular surgical trial of
fragile neonates. The standard perioperative course for
these patients includes many clinical states that would
represent SAEs in the CTCAE scoring system. This raised
concerns about the ability to detect any single critical safety
signal in the large stream of reported data and resulted in
a significant reporting burden.
We found that changing to a sentinel SAE reporting strat-
egy allowed us to identify those patients with the highest risk
of death or transplant, as exemplified by the fact that rate of
death and transplant among patients with a sentinel SAE
was significantly higher than in patients with an SAE under
the standard reporting system. This finding was an expected
outcome of the change in reporting, because under the new
system, we were distilling SAE reporting to represent only
the most serious, life-threatening events.
When comparing patients who had only nonserious
events (called AEs in period 1 and complications in periodrdiovascular Surgery c Volume 142, Number 3 533
TABLE 3. Code list complications
Cardiac general
Arrhythmia (recorded if requires medication or treatment)
 Atrial fibrillation
 Atrial flutter
 Supraventricular tachycardia
 Junctional ectopic tachycardia
 Sinus node dysfunction (requiring pacing)
 Atrioventicular block (second or third degree)
 Ventricular tachycardia
 Ventricular fibrillation
Mediastinum
 Hemopericardium (requiring intervention, includes postoperative
mediastinal hemorrhage)
 Pericardial effusion (requiring drainage)
 Postpericardiotomy syndrome (requiring treatment)
Cardiac performance
 Hypotension (<40 mm Hg for neonates;<50 mm Hg after stage II
surgery)
 Hypertension (requiring long-term therapy, ie,>30 days after
discharge, therapy should be at therapeutic doses and specifically
prescribed for the treatment of hypertension)
 RV dysfunction (requiring escalation or initiation of therapy, not to
include immediate postoperative dysfunction routinely associated
with cardiopulmonary bypass)
 Semilunar valve insufficiency or stenosis (requiring treatment
initiation or escalation)
 Atrioventricular valve insufficiency or stenosis (requiring treatment
initiation or escalation)
 Prosthetic valve dysfunction
Great vessels
 Superior vena cava stenosis (anatomic, symptomatic, ‘‘superior vena
cava syndrome’’)
 Superior vena cava occlusion
 Inferior vena cava occlusion
 Other cardiovascular
Respiratory
 Chronic respiratory failure (intubated for>2 weeks after surgery)
 Chylothorax (postoperative accumulation of chylous fluid in the
pleural space requiring intervention whether by evacuation, dietary
change, and/or medical treatment)
 Hemothorax (requiring drainage)
 Phrenic nerve injury/diaphragmatic paralysis (newly elevated
diaphragm on chest x-ray film)
 Pleural effusion (requiring drainage>7 days after surgery, other)
 Pneumothorax (requiring tube insertion)
 Tracheal injury
 Vocal cord injury (direct visualization)
 Airway obstruction (requiring a significant intervention)
 Hypoxia (requiring readmission or escalation of care)
 Other respiratory
Neurologic
 Choreoathetosis/posturing (moderate involuntary movements
interfering with function)
 Coma
 Intracranial bleeding (confirmed by imaging)
(Continued)
TABLE 3. Continued
 Seizure(s) (confirmed by electroencephalogram or obvious motor
signs)
 Stroke (confirmed by imaging study)
 Hydrocephalus (report if CTCAE grade>2)
 Neurologic deficit persisting at discharge not attributed to any of the
above diagnoses
 Other neurologic
Gastrointestinal
 Direct bilirubin>4 mmol/L
 Liver failure (AST, ALT, or GGT>500 U/L)
 Necrotizing enterocolitis, confirmed (pneumatosis or free air)
 Necrotizing enterocolitis, suspected (NPO, antibiotics started)
Other esophageal or bowel perforations not associated with necrotizing
enterocolitis
 Upper gastrointestinal bleed, requiring treatment
 Stricture/stenosis (CTCAE>grade 2)
 Other gastrointestinal
Infectious
 Empyema
 Endocarditis
 Gastroenteritis or enteritis
 Line infection, bacterial (positive blood cultures)
 Line infection, fungal (positive blood cultures with initiation of
therapy)
 Pneumonia, respiratory infection, viral (requiring the initiation of
therapy)
Mediastinitis/wound infection, deep (requiring incision and drainage;
sternal instability)
Wound infection, superficial (erythema, possible tissue separation and
drainage)
 Sepsis, confirmed (positive blood cultures, not line infection)
 Sepsis, clinical with negative cultures
 Urinary tract infection
 Other infection
Renal
Acute renal failure (creatinine>1.5 mg/dL (133 mmol/L) or tripling of
baseline value for<7 days; temporary dialysis)
 Chronic renal failure (creatinine>1.5 mg/dL (133 mmol/L) or tripling
of baseline value for>7 days; long-term dialysis)
 Other renal
Hematologic
 Anemia (hemoglobin<10 gm/L)
 Thrombocytopenia (platelets<50 3 109/L)
 Hematoma (CTCAE grade>2)
Hemorrhage, gastrointestinal (CTCAE grade>2; hemepositive stools)
 Hemorrhage, genitourinary (CTCAE grade>2)
 Hemorrhage, pulmonary/upper respiratory (CTCAE grade>2)
 Other hematologic
Vascular
 Thrombus/thromboembolism
 Vascular, other
Other complication
 Other
RV, Right ventricular; CTCAE, Common Terminology Criteria for Adverse Events;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-
glutamyl transferase; NPO, nothing by mouth.
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TABLE 4. Results of changes in AE reporting from randomization to
discharge from stage II hospitalization
Period 1 Period 2
 Subjects 247 224
 Total follow-up time, mo 956 1060
 Follow-up time, mo mean (SD) 3.9 (2.3) 4.7 (2.3)
 SAEs 406 147
 SAEs incidence, events/subject/month
of follow-up*
0.42 0.14
 Subjects with SAE, n (%) 199 (81) 107 (48)
 AEs 344 N/A
 AE incidence, events/subject/month
of follow-up
0.36 N/A
 Complications N/A 1,059
 Complication incidence, events/subject/month
of follow-up
N/A 1.00
AE, Adverse event; SD, standard deviation; SAE, serious adverse event; N/A, not ap-
plicable. *P<.001 for period 1 versus period 2.
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D2), we found that these 2 groups were homogeneous with
regard to risk, based on their similar rates of death and trans-
plant. Additionally, the events classified as SAEs in period
1, for which the classification changed to ‘‘complication’’ in
period 2, were more similar to nonserious AEs than to
SAEs, providing further verification that we had success-
fully focused the SAE reporting process on the highest-
risk events.
The new system also allowed study coordinators and in-
vestigators to focus their time and efforts on reporting and
responding to the most severe events. The 64% reduction
in the volume of SAEs reported, with no change in the infor-
mation requested on SAE reports, suggests that study coor-
dinator time for reporting SAEs could have been reduced by
as much as two-thirds, although this was not measured di-
rectly. Other perceived efficiencies were gained, including
a decrease in reporting burden to local IRBs and decreased
review time by IRBs, the medical monitor, and the DSMB.
Changing to a system of specified sentinel events also, by
design, decreased the variability in what was reported as an
SAE across sites. Site investigators, typically congenital
heart surgeons or pediatric cardiac intensivists, were under-
standably accustomed to thinking in terms of a normal post-
operative course, as opposed to what would be normal for
a healthy nonhospitalized neonate. This led to some sites re-
porting events or procedures such as gastrostomy tube place-
ment or diaphragm plication as SAEs, while other sites
considered the same event or procedure to be part of typical
postoperative care and thus did not report it. During period 1,
a considerable amount of time was spent attempting to har-
monize the types of events reported.This problemwas solved
with the sentinel SAE strategy used in period 2, because sites
were reporting on a small number of predefined events.
There is a large body of literature devoted to patient
safety and clinical error prevention designed to minimize
morbidity and mortality and to evaluate quality of care.The Journal of Thoracic and CaEnsuring the safety of subjects in clinical trials has received
less attention. AE reporting is one of the main tools to assess
safety, but the good clinical practice principles that govern
the conduct of clinical research were developed primarily
for drug trials. Furthermore, most clinical trials have been
conducted in adults. It was not until approximately 1 decade
ago that pediatric research began to be emphasized as a mat-
ter of policy by the NIH and by Congress with the passage
of the Food and Drug Administration Modernization Act of
1997, the Best Pharmaceuticals for Children Act (2002),20
and the Pediatric Research Equity Act (2003).21 We believe
that our approach may represent a useful paradigm for fu-
ture surgical trials, as well as for trials of critically ill partic-
ipants in general. This approach has already been adopted
by another NHLBI-funded trial of therapeutic hypothermia
in children after cardiac arrest22 (personal communication
from Victoria Pemberton, December 28, 2008).
LIMITATIONS
This was not a prospectively designed comparison, but
rather reflects a retrospective evaluation of a practical
change made in AE reporting procedures during the con-
duct of a clinical trial. Therefore, we do not know whether
unmeasured factors could have influenced our results and
thus the generalizability of the findings. Nonetheless, our
results consistently support the benefits of the change. Fur-
thermore, there is no evidence from these data or other trial
monitoring data that there were any untoward effects of the
reporting change.
CONCLUSIONS
In a randomized surgical trial in neonates with complex
congenital heart disease, expedited reporting of AEs based
on existing methods was found to be impractical. An over-
whelming volume of data was generated, which not only in-
creased the chance of error, but also risked obscuring true
indicators of concern. Thus, a novel methodology was de-
veloped to effectively and efficiently capture appropriate
events. This new technique relies on monitoring a small
number of clearly defined sentinel SAEs and resulted in
comparable identification of clinically relevant events while
decreasing the administrative reporting burden. This meth-
odology may be of benefit in trials evaluating surgical or
device-based interventions and in critically ill populations
where many common clinical events would qualify as
SAEs in the context of a drug trial. Additional research on
this methodology as well as on pediatric AE reporting in
general is needed.
We thank Christine Kang, MDiv, for assisting in the preparation
and submission of this manuscript.
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